Update: Novo Nordisk Wins Dutch Injunction in Ceban Semaglutide Patent Case

MT Newswires Live

Aug 07

(Updates with Ceban's response in the last paragraph)

Novo Nordisk (NVO) said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie B.V. in a patent-infringement case involving its compounded semaglutide nasal spray.

The District Court of The Hague ordered Ceban to stop selling the nasal spray immediately, noting that Ceban infringed Novo Nordisk's supplementary protection certificate covering semaglutide, Novo said.

Novo Nordisk said that under the ruling, Ceban has to remove references to the product from relevant listings and websites, provide information about its commercial supply chain, and reimburse its legal costs.

"We have studied the decision and accept the court's ruling. Since this medicinal product is an insignificant part of our business, the financial impact of this ruling is immaterial," a spokesperson for Ceban Pharmaceuticals, parent company of Ceban Ziekenhuisfarmacie, said Friday in an emailed statement.

Price: 47.21, Change: +1.24, Percent Change: +2.70

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2657642465"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2657642465\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2657642465?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 23:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657642465","market":"hk","top_or_hot":-1,"title":"Update: Novo Nordisk Wins Dutch Injunction in Ceban Semaglutide Patent Case","media":"MT Newswires Live","content":"<html><body><p> (Updates with Ceban's response in the last paragraph)</p><p><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie B.V. in a patent-infringement case involving its compounded semaglutide nasal spray.</p><p>The District Court of The Hague ordered Ceban to stop selling the nasal spray immediately, noting that Ceban infringed Novo Nordisk's supplementary protection certificate covering semaglutide, Novo said.</p><p>Novo Nordisk said that under the ruling, Ceban has to remove references to the product from relevant listings and websites, provide information about its commercial supply chain, and reimburse its legal costs.</p><p>\"We have studied the decision and accept the court's ruling. Since this medicinal product is an insignificant part of our business, the financial impact of this ruling is immaterial,\" a spokesperson for Ceban Pharmaceuticals, parent company of Ceban Ziekenhuisfarmacie, said Friday in an emailed statement.</p><p>Price: 47.21, Change: +1.24, Percent Change: +2.70</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Update: Novo Nordisk Wins Dutch Injunction in Ceban Semaglutide Patent Case</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpdate: Novo Nordisk Wins Dutch Injunction in Ceban Semaglutide Patent Case\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-07 23:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> (Updates with Ceban's response in the last paragraph)</p><p><a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> (NVO) said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie B.V. in a patent-infringement case involving its compounded semaglutide nasal spray.</p><p>The District Court of The Hague ordered Ceban to stop selling the nasal spray immediately, noting that Ceban infringed Novo Nordisk's supplementary protection certificate covering semaglutide, Novo said.</p><p>Novo Nordisk said that under the ruling, Ceban has to remove references to the product from relevant listings and websites, provide information about its commercial supply chain, and reimburse its legal costs.</p><p>\"We have studied the decision and accept the court's ruling. Since this medicinal product is an insignificant part of our business, the financial impact of this ruling is immaterial,\" a spokesperson for Ceban Pharmaceuticals, parent company of Ceban Ziekenhuisfarmacie, said Friday in an emailed statement.</p><p>Price: 47.21, Change: +1.24, Percent Change: +2.70</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2657642465","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657642465","pubTimestamp":1786114897,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Novo Nordisk  said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie B.V. in a patent-infringement case involving its compounded semaglutide nasal spray.The District Court of The Hague ordered Ceban to stop selling the nasal spray immediately, noting that Ceban infringed Novo Nordisk's supplementary protection certificate covering semaglutide, Novo said.Novo Nordisk said that under the ruling, Ceban has to remove references to the product from relevant listings and websites, provide information about its commercial supply chain, and reimburse its legal costs.\"We have studied the decision and accept the court's ruling. Since this medicinal product is an insignificant part of our business, the financial impact of this ruling is immaterial,\" a spokesperson for Ceban Pharmaceuticals, parent company of Ceban Ziekenhuisfarmacie, said Friday in an emailed statement.Price: 47.21, Change: +1.24, Percent Change: +2.70","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","NVOH":"Novo Nordisk A/S B Shares ADRhedged","OZEM":"Roundhill GLP-1 & Weight Loss ETF","BK4588":"碎股","BK4599":"减肥药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","PPH":"VanEck Pharmaceutical ETF","BK4585":"ETF&股票定投概念","NVOX":"2倍做多NVO ETF-Defiance","NVO":"诺和诺德","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4532":"文艺复兴科技持仓"},"translate_title":"更新：诺和诺德在 Ceban Semaglutide 专利案中赢得荷兰禁令","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.96,"NVOH":0.6,"NVOX":0.6,"PPH":0.6,"OZEM":0.6,"THNR":0.6},"content_text":"(Updates with Ceban's response in the last paragraph)Novo Nordisk (NVO) said Wednesday it won a preliminary injunction in the Netherlands against Ceban Ziekenhuisfarmacie B.V. in a patent-infringement case involving its compounded semaglutide nasal spray.The District Court of The Hague ordered Ceban to stop selling the nasal spray immediately, noting that Ceban infringed Novo Nordisk's supplementary protection certificate covering semaglutide, Novo said.Novo Nordisk said that under the ruling, Ceban has to remove references to the product from relevant listings and websites, provide information about its commercial supply chain, and reimburse its legal costs.\"We have studied the decision and accept the court's ruling. Since this medicinal product is an insignificant part of our business, the financial impact of this ruling is immaterial,\" a spokesperson for Ceban Pharmaceuticals, parent company of Ceban Ziekenhuisfarmacie, said Friday in an emailed statement.Price: 47.21, Change: +1.24, Percent Change: +2.70","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}